BACKGROUND: Carbonic anhydrase IX (CA IX) is a hypoxia-induced enzyme regulating tumour pH and facilitating cell migration/invasion. It is primarily expressed as a transmembrane cell-surface protein, but its ectodomain can be shed by ADAM17 to extracellular space. This study aims to elucidate the impact of CA IX shedding on cancer cells. METHODS: We generated a non-shed CA IX mutant by deletion of amino acids 393-402 from the stalk region and studied its phenotypic effects compared to full-length, shedding-competent CA IX using a range of assays based on immunodetection, confocal microscopy, in vitro real-time cell monitoring and in vivo tumour cell inoculation using xenografted NMRI and C57BL/6J female mice. RESULTS: We demonstrated that the impairment of shedding does not alter the ability of CA IX to bind ADAM17, internalise, form oligomers and regulate pH, but induces cancer-promoting changes in extracellular proteome. Moreover, it affects intrinsic properties of cells expressing the non-shed variant, in terms of their increased ability to migrate, generate primary tumours and form metastatic lesions in lungs. CONCLUSIONS: Our results show that the ectodomain shedding controls pro-tumorigenic and pro-metastatic roles of the cell-associated CA IX and suggest that this phenomenon should be considered when developing CA IX-targeted therapeutic strategies.

Department of Tumor Biology Institute of Virology Biomedical Research Center Slovak Academy of Sciences Dubravska cesta 9 84505 Bratislava Slovakia

Institute of Pharmacology and Toxicology RWTH Aachen University Wendlingweg 2 52074 Aachen Germany

RECAMO Masaryk Memorial Cancer Institute Zluty kopec 7 65653 Brno Czech Republic

Zobrazit více v PubMed

Hayashida K, Bartlett AH, Chen Y, Park PW. Molecular and cellular mechanisms of ectodomain shedding. Anat. Rec. 2010;293:925–937. PubMed PMC

Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011;32:380–387. PubMed

Arribas J, Borroto A. Protein ectodomain shedding. Chem. Rev. 2002;102:4627–4638. PubMed

Rzymski T, Petry A, Kračun D, Rieß F, Pike L, Harris AL, et al. The unfolded protein response controls induction and activation of ADAM17/TACE by severe hypoxia and ER stress. Oncogene. 2012;31:3621–3634. PubMed

Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat. Rev. Cancer. 2002;2:38–47. PubMed

Wykoff CC, Beasley NJP, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075–7083. PubMed

Zaťovičová M, Sedláková O, Švastová E, Ohraďanová A, Čiampor F, Arribas J, et al. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br. J. Cancer. 2005;93:1267–1276. PubMed PMC

Zaťovičová M, Pastoreková S. Modulation of cell surface density of carbonic anhydrase IX by shedding of the ectodomain and endocytosis. Acta Virol. 2013;57:257–264. PubMed

Pastorek J, Pastoreková S. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. Semin. Cancer Biol. 2015;31:52–64. PubMed

van Kuijk SJA, Yaromina A, Houben R, Niemans R, Lambin P, Dubois LJ. Prognostic significance of carbonic anhydrase IX expression in cancer patients: a meta-analysis. Front. Oncol. 2016;6:69. PubMed PMC

Barathova M, Takacova M, Holotnakova T, Gibadulinova A, Ohradanova A, Zatovicova M, et al. Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype. Br. J. Cancer. 2008;98:129–136. PubMed PMC

Ditte P, Dequiedt F, Švastová E, Hulíková A, Ohraďanová-Repič A, Zaťovičová M, et al. Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res. 2011;71:7558–7567. PubMed

Supuran CT. Structure and function of carbonic anhydrases. Biochem. J. 2016;473:2023–2032. PubMed

Pastoreková S, Ratcliffe PJ, Pastorek J. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int. 2008;101(Suppl):8–15. PubMed

Švastová E, Pastoreková S. Carbonic anhydrase IX: a hypoxia-controlled ‘catalyst’ of cell migration. Cell Adhes. Migr. 2013;7:226–231. PubMed PMC

Švastová E, Hulíková A, Rafajová M, Zaťovičová M, Gibadulinová A, Casini A, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004;577:439–445. PubMed

Swietach P, Wigfield S, Supuran CT, Harris AL, Vaughan-jones RD. Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO 2 diffusion. BJU Int. 2008;1:22–24. PubMed

Swietach P, Patiar S, Supuran CT, Harris AL, Vaughan-Jones RD. The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in three-dimensional tumor cell growths. J. Biol. Chem. 2009;284:20299–20310. PubMed PMC

Orlowski A, De Giusti VC, Morgan PE, Aiello EA, Álvarez BV. Binding of carbonic anhydrase IX to extracellular loop 4 of the NBCe1 Na + /HCO 3 − cotransporter enhances NBCe1-mediated HCO 3—influx in the rat heart. Am. J. Physiol. Cell Physiol. 2012;303:C69–C80. PubMed

Jamali S, Klier M, Ames S, Felipe Barros L, McKenna R, Deitmer JW, et al. Hypoxia-induced carbonic anhydrase IX facilitates lactate flux in human breast cancer cells by non-catalytic function. Sci. Rep. 2015;5:13605. PubMed PMC

Fang JS, Gillies RD, Gatenby RA. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin. Cancer Biol. 2008;18:330–337. PubMed PMC

Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 2009;69:358–368. PubMed

Parks SK, Cormerais Y, Marchiq I, Pouyssegur J. Hypoxia optimises tumour growth by controlling nutrient import and acidic metabolite export. Mol. Asp. Med. 2016;47–48:3–14. PubMed

Stock C, Schwab A. Protons make tumor cells move like clockwork. Pflug. Arch. Eur. J. Physiol. 2009;458:981–992. PubMed

Švastová E, Witarski W, Csaderová L, Košík I, Škvarková L, Hulíková A, et al. Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J. Biol. Chem. 2012;287:3392–3402. PubMed PMC

Radvák P, Repic M, Švastová E, Takáčová M, Csaderová L, Strnad H, et al. Suppression of carbonic anhydrase IX leads to aberrant focal adhesion and decreased invasion of tumor cells. Oncol. Rep. 2013;29:1147–1153. PubMed

Csaderová L, Debreová M, Radvák P, Stano M, Vreštiaková M, Kopáček J, et al. The effect of carbonic anhydrase IX on focal contacts during cell spreading and migration. Front. Physiol. 2013;4:271. PubMed PMC

Swayampakula M, McDonald PC, Vallejo M, Coyaud E, Chafe SC, Westerback A, et al. The interactome of metabolic enzyme carbonic anhydrase IX reveals novel roles in tumor cell migration and invadopodia/MMP14-mediated invasion. Oncogene. 2017;36:6244–6261. PubMed PMC

Ledaki, I., McIntyre, A., Wigfield, S., Buffa, F., McGowan, S., Baban, D. et al. Carbonic anhydrase IX induction defines a heterogeneous cancer cell response to hypoxia and mediates stem cell-like properties and sensitivity to HDAC inhibition. Oncotargethttp://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=4989&path%5B%5D=11380 (2015). PubMed PMC

Vidlickova I, Dequiedt F, Jelenska L, Sedlakova O, Pastorek M, Stuchlik S, et al. Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy. BMC Cancer. 2016;16:239. PubMed PMC

Pastoreková S, Závadová Z, Košťál M, Babusíková O, Závada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology. 1992;187:620–626. PubMed

Závada J, Závadová Z, Pastorek J, Biesová Z, Jez˘ek J, Velek J. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br. J. Cancer. 2000;82:1808–1813. PubMed PMC

Pruessmeyer J, Martin C, Hess FM, Schwarz N, Schmidt S, Kogel T, et al. A Disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells. J. Biol. Chem. 2010;285:555–564. PubMed PMC

Koenen RR, Pruessmeyer J, Soehnlein O, Fraemohs L, Zernecke A, Schwarz N, et al. Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood. 2009;113:4799–4809. PubMed

Borroto A, Ruíz-Paz S, Villanueva de la Torre T, Borrell-Pagès M, Merlos-Suárez A, Pandiella A, et al. Impaired trafficking and activation of tumor necrosis factor-α-converting enzyme in cell mutants defective in protein ectodomain shedding. J. Biol. Chem. 2003;278:25933–25939. PubMed

Tucher J, Linke D, Koudelka T, Cassidy L, Tredup C, Wichert R, et al. LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries. J. Proteome Res. 2014;13:2205–2214. PubMed

Söderberg O, Gullberg M, Jarvius M, Ridderstråle K, Leuchowius K-J, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods. 2006;3:995–1000. PubMed

Zaťovičová M, Tarábková K, Švastová E, Gibadulinová A, Mucha V, Jakubíčková L, et al. Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX*1. J. Immunol. Methods. 2003;282:117–134. PubMed

Švastová E, Žilka N, Zaťovičová M, Gibadulinová A, Čiampor F, Pastorek J, et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin. Exp. Cell Res. 2003;290:332–345. PubMed

Takáčová M, Bartošová M, Škvarková L, Zaťovičová M, Vidličková I, Csaderová L, et al. Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma. Oncol. Lett. 2013;5:191–197. PubMed PMC

Woelber L, Kress K, Kersten JF, Choschzick M, Kilic E, Herwig U, et al. Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer. BMC Cancer. 2011;11:12. PubMed PMC

Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, et al. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer. Breast Cancer Res. 2011;13:R71. PubMed PMC

Kalavska K, Chovanec M, Zatovicova M, Takacova M, Gronesova P, Svetlovska D, et al. Prognostic value of serum carbonic anhydrase IX in testicular germ cell tumor patients. Oncol. Lett. 2016;12:2590–2598. PubMed PMC

Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–691. PubMed PMC

Massagué J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529:298–306. PubMed PMC

Düsterhöft S, Babendreyer A, Giese AA, Flasshove C, Ludwig A. Status update on iRhom and ADAM17: It’s still complicated. Biochim. Biophys. Acta Mol. Cell Res. 2019;1866:1567–1583. PubMed

Scharfenberg F, Helbig A, Sammel M, Benzel J, Schlomann U, Peters F, et al. Degradome of soluble ADAM10 and ADAM17 metalloproteases. Cell Mol. Life Sci. 2019 doi: 10.1007/s00018-019-03184-4. PubMed DOI PMC

Baran P, Nitz R, Grötzinger J, Scheller J, Garbers C. Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling. J. Biol. Chem. 2013;288:14756–68.. PubMed PMC

Zheng Y, Saftig P, Hartmann D, Blobel C. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17) J. Biol. Chem. 2004;279:42898–906.. PubMed

Hinkle CL, Sunnarborg SW, Loiselle D, Parker CE, Stevenson M, Russell WE, et al. Selective roles for tumor necrosis factor alpha-converting enzyme/ADAM17 in the shedding of the epidermal growth factor receptor ligand family: the juxtamembrane stalk determines cleavage efficiency. J. Biol. Chem. 2004;279:24179–88.. PubMed

Santiago-Josefat B, Esselens C, Bech-Serra JJ, Arribas J. Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors. J. Biol. Chem. 2007;282:8325–8331. PubMed

Dombernowsky SL, Samsøe-Petersen J, Petersen CH, Instrell R, Hedegaard A-MB, Thomas L, et al. The sorting protein PACS-2 promotes ErbB signalling by regulating recycling of the metalloproteinase ADAM17. Nat. Commun. 2015;6:7518. PubMed PMC

Marchiq I, Albrengues J, Granja S, Gaggioli C, Pouysségur J, Simon M-P. Knock out of the BASIGIN/CD147 chaperone of lactate/H+ symporters disproves its pro-tumour action via extracellular matrix metalloproteases (MMPs) induction. Oncotarget. 2015;6:24636–24648. PubMed PMC

Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, Basbaum C. The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene. 2004;23:956–963. PubMed

Watnick RS, Rodriguez RK, Wang S, Blois AL, Rangarajan A, Ince T, et al. Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells. Oncogene. 2015;34:2949–2950. PubMed

Yamada PM, Lee K-W. Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. AJP Cell Physiol. 2009;296:C954–C976. PubMed

Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat. Rev. Cancer. 2014;14:329–341. PubMed

Dorai T, Sawczuk IS, Pastorek J, Wiernik PH, Dutcher JP. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur. J. Cancer. 2005;41:2935–2947. PubMed

Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JKV, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc. Natl Acad. Sci. USA. 2007;104:5563–5568. PubMed PMC

Ord JJ, Streeter EH, Roberts ISD, Cranston D, Harris AL. Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. Br. J. Cancer. 2005;93:346–354. PubMed PMC